StreetInsider.com News Articles

Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology

Fri, 16 Oct 2026 08:30:00 -0400

DOYLESTOWN, Pa., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that it will host a virtual panel discussion, "The State of WEE1 Inhibition in Precision Oncology," on Tuesday, October 20, 2026, at 11 am ET.

Disrupting the DNA damage response has become a compelling therapeutic strategy in oncology in recent years and WEE1 inhibitors are among the most promising drugs being developed within this class. Ahead of the

Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology

Fri, 16 Oct 2026 08:30:00 -0400

Ladenburg Thalmann Starts Aprea (APRE) at Buy

Wed, 14 Oct 2026 06:42:26 -0400

Ladenburg Thalmann analyst Kevin DeGeeter initiates coverage on Aprea (NASDAQ: APRE) with a Buy rating and a price target of $2.00.

For an analyst ratings summary and ratings history on Aprea click here. For more ratings news on Aprea click here.

Shares of Aprea closed at $0.60 yesterday.

Aprea Therapeutics to Present at October Conferences

Mon, 05 Oct 2026 08:30:00 -0400

Company to participate in 2026 Maxim Growth Summit (October 14) and Regional Biotechnology Conference (October 15)

DOYLESTOWN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that Oren Gilad PhD, President and CEO, will participate in the 2026 Maxim Growth Summit, to take place October 12-14 in New York City and the Regional Biotechnology Conference, to take place October 15 in Doylestown, PA.

Maxim

Aprea Therapeutics to Present at October Conferences

Mon, 05 Oct 2026 08:30:00 -0400

Company to participate in 2026 Maxim Growth Summit (October 14) and Regional Biotechnology Conference (October 15)
DOYLESTOWN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that Oren Gilad PhD, President and CEO, will participate in the 2026 Maxim Growth Summit, to take place October 12-14 in New York City and the Regional Biotechnology Conference, to take place October 15 in Doylestown, PA.

Maxim

Aprea to present Phase 1 data on APR-1051 at EORTC-NCI-AACR symposium

Tue, 22 Sep 2026 08:30:39 -0400

Aprea Therapeutics, Inc. (Nasdaq: APRE) announced that updated interim results from its ongoing Phase 1 ACESOT-1051 study of WEE1 inhibitor APR-1051 will be presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, scheduled for November 18-20, 2026, in Barcelona, Spain.

The study involves patients with advanced solid tumors. The presentation has been selected for a plenary oral session on November 20, 2026, from 3:00 PM to 3:10 PM CET in Room 111 + 112 at the CCIB convention center in Barcelona.

Timothy A. Yap, MBBS, PhD, FRCP, from the Department of Investigational Cancer Therapeutics at The University of Texas

Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium

Tue, 22 Sep 2026 08:30:00 -0400

DOYLESTOWN, Pa., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that an abstract featuring updated interim results from the ongoing Phase 1 ACESOT-1051 study of its WEE1 inhibitor APR-1051 in patients with advanced solid tumors has been accepted for oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), to take place November 18-20, 2026, in Barcelona, Spain.

“We look forward to presenting

Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium

Tue, 22 Sep 2026 08:30:00 -0400

DOYLESTOWN, Pa., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that an abstract featuring updated interim results from the ongoing Phase 1 ACESOT-1051 study of its WEE1 inhibitor APR-1051 in patients with advanced solid tumors has been accepted for oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), to take place November 18-20, 2026, in Barcelona, Spain.

“We look forward to presenting

Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

Thu, 10 Sep 2026 08:00:00 -0400

DOYLESTOWN, Pa., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that Oren Gilad, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference, to be held in person and virtually September 14-16, 2026.

Presentation Details

Webcast link: Click here available from 4:30pm ET on Monday, September 14, 2026

Investors can register for the conference

Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

Thu, 10 Sep 2026 08:00:00 -0400

DOYLESTOWN, Pa., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that Oren Gilad, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference, to be held in person and virtually September 14-16, 2026.

Presentation Details

Webcast link: Click here available from 4:30pm ET on Monday, September 14, 2026

Investors can register for the conference

Form 8-K Aprea Therapeutics, Inc. For: Aug 28

Fri, 28 Aug 2026 08:30:00 -0400
si-local-file:///var/storage/secattach/20260828/26993358.html

Form 8-K Aprea Therapeutics, Inc. For: Aug 28

Fri, 28 Aug 2026 08:30:00 -0400
si-local-file:///var/storage/secattach/20260828/26993358.html

Aprea Therapeutics updates patent portfolio to 28 issued patents

Fri, 28 Aug 2026 08:16:48 -0400

Aprea Therapeutics, Inc. (Nasdaq: APRE) disclosed an update on its patent portfolio, reporting 28 issued and 30 pending patents across its oncology programs, according to a company statement.
The company's WEE1 kinase inhibitor program is covered by two pending U.S. patent applications, one pending U.S. provisional application, two granted non-U.S. patents in Australia and Korea, and 12 pending non-U.S. patent applications. If granted, this family of patents would expire in 2047, excluding any regulatory exclusivities. The program's lead compound, APR-1051, is currently being evaluated in the ACESOT-1051 Phase 1 clinical trial in advanced and metastatic solid tumors.
Aprea's ATR inhibitor program holds

Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs

Fri, 28 Aug 2026 08:15:00 -0400

Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents
DOYLESTOWN, Pa., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today provided an update on its existing patent portfolio.

“Our expanding patent portfolio reflects Aprea’s commitment to innovation and building a differentiated leadership position in precision medicine,” said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. “A strong global intellectual property portfolio is a critical component

Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs

Fri, 28 Aug 2026 08:15:00 -0400

Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents
DOYLESTOWN, Pa., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today provided an update on its existing patent portfolio.

“Our expanding patent portfolio reflects Aprea’s commitment to innovation and building a differentiated leadership position in precision medicine,” said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. “A strong global intellectual property portfolio is a critical component

Form SCHEDULE 13G/A Aprea Therapeutics, Inc. Filed by: LYTTON LAURENCE W

Thu, 13 Aug 2026 14:27:00 -0400
si-local-file:///var/storage/secattach/20260813/26919885.html

Form SCHEDULE 13G/A Aprea Therapeutics, Inc. Filed by: LYTTON LAURENCE W

Thu, 13 Aug 2026 14:27:00 -0400
si-local-file:///var/storage/secattach/20260813/26919885.html

Form 10-Q Aprea Therapeutics, Inc. For: Jun 30

Wed, 12 Aug 2026 08:41:00 -0400
si-local-file:///var/storage/secattach/20260812/26909570.html

Form 10-Q Aprea Therapeutics, Inc. For: Jun 30

Wed, 12 Aug 2026 08:41:00 -0400
si-local-file:///var/storage/secattach/20260812/26909570.html

Form 8-K Aprea Therapeutics, Inc. For: Aug 12

Wed, 12 Aug 2026 08:35:00 -0400
si-local-file:///var/storage/secattach/20260812/26909531.html

Form 8-K Aprea Therapeutics, Inc. For: Aug 12

Wed, 12 Aug 2026 08:35:00 -0400
si-local-file:///var/storage/secattach/20260812/26909531.html

Aprea Therapeutics Announces Second Quarter 2026 Financial Results

Wed, 12 Aug 2026 08:30:00 -0400

Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances

Aprea plans to advance APR-1051 in uterine serous carcinoma (USC), and Cyclin E–overexpressing platinum-resistant ovarian cancer (PROC) while also evaluating combination regimens with standard of care in HPV-positive head and neck cancer and colorectal cancer

Updated Phase 1 data presented at ASCO 2026 showed early single-agent activity for APR-1051, including partial responses and disease stabilization, with a manageable tolerability profile

$41.2 million in cash and cash equivalents as of June 30, 2026

DOYLESTOWN, Pa.,

Aprea Therapeutics Announces Second Quarter 2026 Financial Results

Wed, 12 Aug 2026 08:30:00 -0400

Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances

Aprea plans to advance APR-1051 in uterine serous carcinoma (USC), and Cyclin E–overexpressing platinum-resistant ovarian cancer (PROC) while also evaluating combination regimens with standard of care in HPV-positive head and neck cancer and colorectal cancer

Updated Phase 1 data presented at ASCO 2026 showed early single-agent activity for APR-1051, including partial responses and disease stabilization, with a manageable tolerability profile

$41.2 million in cash and cash equivalents as of June 30, 2026

DOYLESTOWN, Pa.,

Lipocine names former Johnson & Johnson executive to its board

Mon, 03 Aug 2026 08:00:56 -0400

Lipocine Inc. (NASDAQ: LPCN) announced the appointment of Michael J. Grissinger to its board of directors, effective Aug. 3, 2026, according to a company press release.

Grissinger spent more than two decades at Johnson & Johnson, where he held senior roles including Vice President and Head of Worldwide Pharmaceutical Licensing and Vice President and Head of Worldwide Pharmaceutical Corporate Development and M&A. Before Johnson & Johnson, he spent 12 years at Ciba-Geigy in finance, marketing, and business development.

He currently serves on the boards of Aprea Therapeutics (NASDAQ: APRE) and Adicet Bio (NASDAQ: ACET), and advises several privately held biotech companies. Grissinger

Lipocine names former Johnson & Johnson executive to its board

Mon, 03 Aug 2026 08:00:56 -0400

Lipocine Inc. (NASDAQ: LPCN) announced the appointment of Michael J. Grissinger to its board of directors, effective Aug. 3, 2026, according to a company press release.

Grissinger spent more than two decades at Johnson & Johnson, where he held senior roles including Vice President and Head of Worldwide Pharmaceutical Licensing and Vice President and Head of Worldwide Pharmaceutical Corporate Development and M&A. Before Johnson & Johnson, he spent 12 years at Ciba-Geigy in finance, marketing, and business development.

He currently serves on the boards of Aprea Therapeutics (NASDAQ: APRE) and Adicet Bio (NASDAQ: ACET), and advises several privately held biotech companies. Grissinger